Bio-Techne vs Neogen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bio-Techne Corp (TECH)

Q3 202628 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

August 202628 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Latest28 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Q2 202625 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

June 202625 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

25 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

Neogen Corporation (NEOG)

Q3 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

August 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Latest24 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.